As shown in Table 3, high expression of EPHA2 (HR = 1.49, 95% CI: 1.08–2.06, P = 0.016), EPHA3 (HR = 1.55, 95% CI: 1.12–2.15, P = 0.008), EPHA4 (HR = 1.95, 95% CI: 1.2–3.18, P = 0.0064), EFNA3 (HR = 1.96, 95% CI: 1.44–2.65, P < 0.001), and EFNA4 (HR = 1.4, 95% CI: 1.02–1.93, P = 0.037) and low expression of EPHA5 (HR = 0.43, 95% CI: 0.25–0.93, P = 0.002), EPHA6 (HR = 0.51, 95% CI: 0.27–0.95, P = 0.03), and EPHA10 (HR = 0.48, 95% CI: 0.29–0.8, P = 0.0043) were significantly correlated with poor RFS in BrCa patients treated with adjuvant chemotherapy. Here, EPHA5 is linked to invasive breast carcinoma.